jd5037 and Prader-Willi-Syndrome

jd5037 has been researched along with Prader-Willi-Syndrome* in 1 studies

Other Studies

1 other study(ies) available for jd5037 and Prader-Willi-Syndrome

Article	Year
Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome. Molecular metabolism, 2016, Volume: 5, Issue:12 Extreme obesity is a core phenotypic feature of Prader-Willi syndrome (PWS). Among numerous metabolic regulators, the endocannabinoid (eCB) system is critically involved in controlling feeding, body weight, and energy metabolism, and a globally acting cannabinoid-1 receptor (CB. We studied eCB 'tone' in individuals with PWS and in the. Dysregulation of the eCB/CB Topics: Adult; Animals; Antigens, Neoplasm; Arachidonic Acids; Body Weight; Case-Control Studies; Disease Models, Animal; Endocannabinoids; Female; Glycerides; Humans; Hypothalamus; Male; Mice; Mice, Inbred C57BL; Prader-Willi Syndrome; Proteins; Pyrazoles; Receptor, Cannabinoid, CB1; Sulfonamides; Weight Loss	2016

Article

Year

Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome.

Molecular metabolism, 2016, Volume: 5, Issue:12

Extreme obesity is a core phenotypic feature of Prader-Willi syndrome (PWS). Among numerous metabolic regulators, the endocannabinoid (eCB) system is critically involved in controlling feeding, body weight, and energy metabolism, and a globally acting cannabinoid-1 receptor (CB. We studied eCB 'tone' in individuals with PWS and in the. Dysregulation of the eCB/CB

Topics: Adult; Animals; Antigens, Neoplasm; Arachidonic Acids; Body Weight; Case-Control Studies; Disease Models, Animal; Endocannabinoids; Female; Glycerides; Humans; Hypothalamus; Male; Mice; Mice, Inbred C57BL; Prader-Willi Syndrome; Proteins; Pyrazoles; Receptor, Cannabinoid, CB1; Sulfonamides; Weight Loss

2016